Literature DB >> 10482274

Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease.

R Mayeux1, M X Tang, D M Jacobs, J Manly, K Bell, C Merchant, S A Small, Y Stern, H M Wisniewski, P D Mehta.   

Abstract

Mutations in the amyloid precursor protein and presenilin 1 and 2 genes result in elevated plasma levels of the amyloid beta-peptide species terminating at amino acid residue 42 (A beta1-42). In a longitudinal study of unrelated elderly individuals, those who subsequently developed Alzheimer's disease had higher plasma levels of A beta1-42 at entry than did those who remained free of dementia. The results indicate that elevated plasma levels of the released A beta peptide A beta1-42 may be detected several years before the onset of symptoms, supporting that extracellular A beta1-42 plays an important role in the pathogenesis of late-onset Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482274     DOI: 10.1002/1531-8249(199909)46:3<412::aid-ana19>3.0.co;2-a

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  79 in total

Review 1.  Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

Authors:  Richard Mayeux; Nicole Schupf
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism.

Authors:  Y M Kuo; T A Kokjohn; M D Watson; A S Woods; R J Cotter; L I Sue; W M Kalback; M R Emmerling; T G Beach; A E Roher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 3.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

Review 4.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

5.  Elevation in plasma Abeta42 in geriatric depression: a pilot study.

Authors:  Nunzio Pomara; P Murali Doraiswamy; Lisa M Willoughby; Amy E Roth; Benoit H Mulsant; John J Sidtis; Pankaj D Mehta; Charles F Reynolds; Bruce G Pollock
Journal:  Neurochem Res       Date:  2006-04-01       Impact factor: 3.996

6.  Amyloid-associated depression: a prodromal depression of Alzheimer disease?

Authors:  Xiaoyan Sun; David C Steffens; Rhoda Au; Marshal Folstein; Paul Summergrad; Jacqueline Yee; Irwin Rosenberg; D Mkaya Mwamburi; Wei Qiao Qiu
Journal:  Arch Gen Psychiatry       Date:  2008-05

7.  Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury.

Authors:  Annika Olsson; Ludvig Csajbok; Martin Ost; Kina Höglund; Karin Nylén; Lars Rosengren; Bengt Nellgård; Kaj Blennow
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

8.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

Review 9.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

10.  Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees.

Authors:  Nilüfer Ertekin-Taner; James Ronald; Hideaki Asahara; Linda Younkin; Maria Hella; Shushant Jain; Eugene Gnida; Samuel Younkin; Daniel Fadale; Yasumasa Ohyagi; Adam Singleton; Leah Scanlin; Mariza de Andrade; Ronald Petersen; Neill Graff-Radford; Michael Hutton; Steven Younkin
Journal:  Hum Mol Genet       Date:  2003-10-14       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.